Home
About
Pricing
Log In

What are you looking for?

Home
Pricing
Back
Compare AU

Compare DRUG vs. RGOS

Compare shares and ETFs on the ASX that you can trade on Pearler.

Betashares Global Healthcare Currency Hedged ETF

ASX

Buy

Buy

Overview
Performance

Overview

When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Betashares Global Healthcare Currency Hedged ETF (DRUG) and the Russell Sust Global Opportunities Complex ETF (RGOS). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.

Community Stats

DRUG

RGOS

Popularity

Low

N/A

Pearlers invested

79

0

Median incremental investment

$736.96

$0

Median investment frequency

Monthly

N/A

Median total investment

$2,282.12

$0

Average age group

> 35

N/A

Key Summary

DRUG

RGOS

Strategy

DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. The ETF currently has 184.38m in AUM and 55 holdings. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars.

RGOS.AX was created on 2024-04-12 by Russell. The fund's investment portfolio concentrates primarily on total market equity. The Fund aims to outperform the Funds benchmark, before costs and tax, over the long term by providing exposure to a diversified portfolio of predominantly international shares.

Top 3 holdings

AUD - AUSTRALIA DOLLAR (0 %)

BRL - BRAZILIAN REAL (0 %)

CHF - SWISS FRANC (0 %)

Microsoft Corp (4.14 %)

Apple Inc (3.90 %)

NVIDIA Corp (3.62 %)

Top 3 industries

Other (75.91 %)

Communication Services (33.53 %)

Health Care (23.80 %)

Top 3 countries

United States (72.30 %)

Switzerland (11.31 %)

United Kingdom of Great Britain and Northern Ireland (5.57 %)

United States (64.01 %)

Japan (5.01 %)

France (4.44 %)

Management fee

0.57 %

0 %

Key Summary

DRUG

RGOS

Issuer

BetaShares

Russell

Tracking index

Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD

Asset class

ETF

ETF

Management fee

0.57 %

0 %

Price

$9.80

$22.08

Size

$192.118 million

N/A

10Y return

122.73 %

N/A

Annual distribution yield (5Y)

1.82 %

6.04 %

Market

ASX

ASX

First listed date

08/08/2016

15/04/2024

Purchase fee

$6.50

$6.50

Community Stats

DRUG

RGOS

Popularity

Low

N/A

Pearlers invested

79

0

Median incremental investment

$736.96

$0

Median investment frequency

Monthly

N/A

Median total investment

$2,282.12

$0

Average age group

> 35

N/A

Pros and Cons

DRUG

RGOS

Pros

  • Higher exposure to US market

  • Higher price growth

  • Higher exposure to AU market

  • Lower management fee

  • Higher distribution yield

Cons

  • Lower exposure to AU market

  • Higher management fee

  • Lower distribution yield

  • Lower exposure to US market

  • Lower price growth

DRUG

RGOS

Lower exposure to AU market

Higher exposure to AU market

Higher exposure to US market

Lower exposure to US market

Higher management fee

Lower management fee

Higher price growth

Lower price growth

Lower distribution yield

Higher distribution yield